Posted by Michael Wonder on 08 Jun 2022
The UK MHRA, Australian TGA and Health Canada approve Kimmtrak (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
8 June 2022 - Kimmtrak demonstrated statistically and clinically meaningful overall survival benefit, hazard ratio of 0.51, with median overall survival of almost 22 months.
Immunocore today announces that the United Kingdom’s MHRA, the TGA in Australia and Health Canada have granted marketing authorisation for Kimmtrak (tebentafusp) for the treatment of HLA-A*02:01 positive adult patients with unresectable or metastatic uveal melanoma.
